LSFG in Patients With Normal Tension Glaucoma Tension Glaucoma
Laser Speckle Flowgraphy in Patients With Normal Tension Glaucoma - a Pilot Study
1 other identifier
interventional
40
1 country
1
Brief Summary
Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing evidence that dysfunction of ocular microcirculation in the optic nerve influences the progression of glaucoma. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the optic disc in Japanese glaucoma patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
October 19, 2017
CompletedFirst Posted
Study publicly available on registry
October 24, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedOctober 24, 2017
October 1, 2017
11 months
October 19, 2017
October 19, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Mean blur ratio (LSFG)
4 seconds
Secondary Outcomes (1)
Pulse-waveform parameters (LSFG)
4 seconds
Interventions
A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
Eligibility Criteria
You may qualify if:
- Caucasian men and women aged over 50 years
- Subject is generally healthy with no current significant or a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination. A significant disorder is defined as a disease or medical condition associated with impaired health status, requiring regular or current medical treatment and/or follow up. For the purposes of this study, an investigator may classify a medical condition as a nonsignificant disorder despite the fact that the subject receives treatment. Subjects having controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or 90-99 mmHg diastolic) are eligible for participation in this study
- Normal open angle in a gonioscopic examination
- Presence of glaucomatous optic disc changes in biomicroscopy and
- Visual field defects in at least two visual field examinations (Reliability criteria: fixation errors \< 20%, false positives \< 15%, and false negatives \< 33%) Or
- Abnormal circumpapillary retinal nerve fiber layer thinning (RNFL evaluated by OCT)
You may not qualify if:
- History of ocular or systemic disease causing optic nerve damage
- History of IOP greater than 21 mm Hg (corrected by CCT)
- Participation in a clinical trial in the 3 weeks preceding the study
- Ocular surgery (including intravitreal injection) during the 3 months preceding the study
- Ametropia \> 6 Dpt
- Smoking
- pre- or perimenopausal women
- Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
- Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading \> 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
- Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
- Blood donation in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Ocular infection or clinically significant inflammation
- Pregnancy, planned pregnancy or lactating
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AKh Linz
Linz, Upper Austria, 4021, Austria
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
October 19, 2017
First Posted
October 24, 2017
Study Start
January 1, 2017
Primary Completion
November 20, 2017
Study Completion
December 1, 2017
Last Updated
October 24, 2017
Record last verified: 2017-10
Data Sharing
- IPD Sharing
- Will not share